Annonce • Jul 29
KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:A225430) announces an Equity Buyback for 207,612 shares, for KRW 300 million. KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:A225430) announces a share repurchase program. Under the program, the company will repurchase up to207,612 for KRW 300 million worth of its shares. The shares will be repurchased at a price of KRW 1,445 per share. The purpose of the program is enhancing shareholder value and stabilizing stock prices. The program will expire on September 10, 2026. As of July 27, 2026, the company had no shares in treasury within scope available for dividend or under other acquisitions. Annonce • Jul 16
KMPHARMACEUTICAL Co.,Ltd. announced that it expects to receive KRW 999.999765 million in funding KMPHARMACEUTICAL Co.,Ltd. announces a private placement to issue 908,265 Common Shares at an issue price of KRW 1,101 for an aggregate gross proceeds of KRW 999,999,765 on July 14, 2026. The transaction involves participation of BAIK BRIAN SEUNG WON for 908,265 Common Shares. The securities under this transaction is subject to one year mandatory lockup. The transaction is expected to close on July 24, 2026. Reported Earnings • Jun 01
First quarter 2026 earnings released: ₩30.00 loss per share (vs ₩30.00 loss in 1Q 2025) First quarter 2026 results: ₩30.00 loss per share (in line with 1Q 2025). Revenue: ₩4.47b (up 9.5% from 1Q 2025). Net loss: ₩834.2m (loss widened 1.2% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings. New Risk • Apr 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 400% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.0b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (400% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩72.1b market cap, or US$48.5m). Annonce • Mar 26
KM Pharmaceutical Co., Ltd. Expands Functional Skincare And Oral Care Product Portfolio KM Pharmaceutical Co. Ltd. is strengthening its global position by expanding into high-value functional product categories across haircare, skincare, and oral care. KM Pharmaceutical is strategically expanding its product portfolio to focus on functional and OTC-driven categories with strong global demand. In haircare, the company is developing products targeting: Hair loss symptom relief (functional scalp care), Scalp inflammation soothing, Scalp barrier strengthening. In skincare, the company is strengthening its functional cosmetic lineup with: Brightening (whitening) solutions, Anti-wrinkle and firming products, Skin barrier repair and strengthening, Anti-inflammatory and soothing formulations for sensitive skin. In oral care, KM Pharmaceutical is expanding its OTC-focused portfolio with: Teeth whitening solutions, Gum disease prevention products, Gingivitis and periodontitis prevention formulations. These categories reflect the company's strategic direction toward high-efficacy, clinically positioned products that align with global consumer demand for functional and results-driven personal care. Skincare continues to be a key growth driver for KM Pharmaceutical's global business. Annonce • Mar 17
KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026 KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.6b market cap, or US$12.7m). New Risk • Jan 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩14.4b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (₩14.4b market cap, or US$9.94m). New Risk • May 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩16.6b market cap, or US$11.9m). Annonce • Mar 18
KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025 KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea New Risk • Mar 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.5b market cap, or US$12.8m). New Risk • Feb 28
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩14.5b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.5b market cap, or US$9.97m). Is New 90 Day High Low • Feb 23
New 90-day low: ₩2,675 The company is down 20% from its price of ₩3,325 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 18
New 90-day low: ₩2,795 The company is down 7.0% from its price of ₩3,020 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period. Is New 90 Day High Low • Dec 23
New 90-day low: ₩2,815 The company is down 5.0% from its price of ₩2,965 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period. Is New 90 Day High Low • Oct 26
New 90-day low: ₩2,845 The company is down 16% from its price of ₩3,380 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period. Is New 90 Day High Low • Sep 22
New 90-day low: ₩3,125 The company is down 3.0% from its price of ₩3,235 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.